BSI-201

BSI-201 is a potent inhibitor of PARP1, or poly (ADP-ribose) polymerase-1, with first-in-class and best-in-class potential as targeted therapy for several types of cancer. 

BSI-201 will be initiating a Phase 3 study in patients with triple negative metastatic breast cancer in Summer 2009. Other clinical trials include multiple Phase 2 studies in breast, ovarian, uterine, and brain tumors. In these studies, BSI-201 has demonstrated activity in multiple types of solid tumors, with prolonged inhibition of its target. BSI-201 has shown a strong safety profile and no significant toxicities attributable to drug in studies of more than 200 patients treated to date with monotherapy, as well as in combination with chemotherapeutic regimens.

PARP is an established target of cancer therapy. Studies have shown that the inhibition of PARP prevents malignant cells from repairing damaged DNA, ultimately leading to impaired tumor growth and cancer cell death.

BSI-201 is a leading candidate in the field of PARP inhibitors and is the furthest along in clinical development of this novel therapeutic approach.

Clinical Status and Recent Milestones of BSI-201